May 22, 2025

New FDA-Approved Topical Foam for Scalp Psoriasis

The FDA has approved roflumilast (ZORYVE) foam 0.3% for once-daily treatment of plaque psoriasis in patients aged 12 and older, including hard-to-treat scalp and body areas..

Conexiant

May 20, 2025

FDA Releases Guidance to Accelerate Generic Drugs

The new guidance is intended to “foster drug product development, ANDA submission and approval, and ultimately provide increased access to generic drugs."

Conexiant

May 19, 2025

Phase 3 Data Backs Roflumilast Foam

Roflumilast foam was found to improve scalp and body psoriasis symptoms with favorable tolerability in patients aged 12 years and older.

Conexiant

May 19, 2025

Zyrtec and Xyzal: FDA Issues Withdrawal Syndrome Warning

A new safety alert highlights the potential for severe itch following discontinuation of long-term cetirizine and levocetirizine use.

Conexiant

May 19, 2025

Bacteria Eat, Exploit Plastic: Study 

A hospital-derived strain of Pseudomonas aeruginosa was found to degrade medical plastic, use it as food, and form stronger biofilms, revealing new risks for device-related infections.

Conexiant

May 09, 2025

Measles Cases Top 1,000 in U.S.

U.S. measles cases surpass 1,000 for the first time since 2019, with Texas at the center of the outbreak.

Reuters

May 05, 2025

Ustekinumab Biosimilar Receives Interchangeability Approval

Selarsdi (ustekinumab-aekn) was approved by the FDA as an interchangeable biosimilar to Stelara (ustekinumab) for all approved indications, including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Conexiant

April 29, 2025

New Oral Option Approved for GCA

The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.

Conexiant

April 24, 2025

FDA Warns of Topical Finasteride Risks

The FDA has issued a safety alert on compounded topical finasteride products, citing adverse events and emphasizing the lack of regulatory approval or safety evaluation.

Conexiant